Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance
Washington State University · with Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · NCT07494084
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–45 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 4
- Target enrollment
- 48
- US sites recruiting
- 1
- Study start
- July 16, 2026
- Record last updated
- September 18, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to examine the impact of timed cortisol release or differently timed cortisol rhythms on insulin resistance in both men and women undergoing sleep restriction. Chronic sleep loss is highly prevalent, affecting 1 in 3 adults in the US. Chronic sleep loss causes stress which induces insulin resistance and leads to obesity and type 2 diabetes. Many factors contribute to sleep loss including shift work, environmental disturbances, sleep/circadian disorders and comorbid medical and mental health conditions. Sleep loss increases the stress hormone cortisol in the evening and decreases daytime testosterone. Examining these hormones in a controlled laboratory environment under different sleep schedules may help researchers find solutions for adults experiencing negative health consequences related to chronic sleep loss.
Being studied: Metyrapone And Hydrocortisone; Dextrose; insulin
Conditions: Shift Work Schedule; Circadian Rhythm; Insulin Resistance; Circadian Misalignment
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Must be between 18-45 years old.
- Has a BMI of 18-25 kg/m2 stable weight over the previous 6 weeks.
- Is physically and psychologically healthy (incl. regular menstrual cycles in women, no clinical disorders and/or illnesses). Women will be studied during the follicular phase of their menstrual cycle.
Menstrual cycle criteria (using PMID 10941950) 18 to 25 years - Cycle variation ≤9 days 26 to 41 years - Cycle variation ≤7 days 42 to 45 years - Cycle variation ≤9 days
- No current medical or drug treatment (to include steroids or hormones of any type including contraceptives), as assessed by questionnaire.
- Has a negative pregnancy test (women), no clinically significant abnormalities in blood and urine, and free of traces of drugs.
- No history of clinically relevant psychiatric illness.
- No previous history of drug or alcohol abuse.
- Not a current smoker.
- No history of brain injury or of learning disability.
- No previous adverse reaction to sleep deprivation, jet lag, shift work or any of the drugs to be administered.
- Not vision or hearing impairment unless corrected back to normal.
- No endocrine disorder (no abnormal thyroid function tests; no abnormal morning blood cortisol; no primary gonadal disease as indicated by serum LH or FSH concentration > 10 or > 15 IU/L, respectively; and no hyperprolactinemia indicated by prolactin > 25 μg/L).
- No sleep or circadian disorder.
- Has good habitual sleep with regular bedtimes (between 6 and 10 hours in duration).
- Not extreme morning- nor extreme evening-type using Horne-Ostberg Morningness-Eveningness criteria.
- No travel across time zones within one month of entering the study.
- No shift work within three months of entering the study.
- No anemia (hematocrit \<38% in men, \<34% in women).
- No blood donation within the previous 8 weeks.
- No concurrent participation in another research study.
Recruiting US locations
Sleep and Performance Research Center
Spokane, WA 99202
Site contact: Olivia Brooks, MS · 509-358-7750 · olivia.brooks@wsu.edu
Study contacts (from the official record)
- Devon A Hansen, PhD · 509-358-7754 · devon.hansen@wsu.edu
- Olivia Brooks, MS · 509-358-7904 · olivia.brooks@wsu.edu
Similar studies in Washington
All diabetes studies in Washington →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Renton, WA + 55 other US sites
- Eligibility basics
- Ages 18–79
- Recruiting
Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes
Medtronic MiniMed, Inc.
- Location
- Renton, WA + 9 other US sites
- Eligibility basics
- Ages 2–80
- RecruitingPhase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S
- Location
- Seattle, WA + 13 other US sites
- Eligibility basics
- Ages 10–18
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Bellevue, WA + 57 other US sites
- Eligibility basics
- Ages 18–80